Navigation Links
Pharmaceuticals - Global Group of Eight (G8) Industry Guide
Date:5/23/2012

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

http://www.reportlinker.com/p0191857/Pharmaceuticals---Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report * Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights The G8 countries contributed $510,182.1 million in 2010 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.9% between 2006 and 2010.

The G8 countries are expected to reach a value of $629,493.5 million in 2015, with a CAGR of 4.3% over the 2010–15 period.Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 52.1% in 2010.

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $265,735.9 million in 2010.

The US is expected to lead the Pharmaceuticals industry in the G8 nations with a value of $346,744.2 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition The pharmaceuticals market consists of ethical drugs for in-patient and out-patient usage, valued at ex-manufacturer prices.

Any currency conversions used within this report have been calculated using 2010 constant exchange rates.

TABLE OF CONTENTSINTRODUCTION 16What is this report about? 16Who is the target reader? 16Market definition 16GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 17PHARMACEUTICALS IN CANADA 24Market overview 24Market value 25Market segmentation 26Market share 27Five forces analysis 28Leading companies 39Market forecasts 50Macroeconomic indicators 51PHARMACEUTICALS IN FRANCE 53Market overview 53Market value 54Market segmentation 55Market share 56Five forces analysis 57Leading companies 68Market forecasts 80Macroeconomic indicators 81PHARMACEUTICALS IN GERMANY 83Market overview 83Market value 84Market segmentation 85Market share 86Five forces analysis 87Leading companies 98Market forecasts 110Macroeconomic indicators 111PHARMACEUTICALS IN ITALY 113Market overview 113Market value 114Market segmentation 115Market share 116Five forces analysis 117Leading companies 128Market forecasts 141Macroeconomic indicators 142PHARMACEUTICALS IN JAPAN 144Market overview 144Market value 145Market segmentation 146Market share 147Five forces analysis 148Leading companies 159Market forecasts 170Macroeconomic indicators 171PHARMACEUTICALS IN RUSSIA 173Market overview 173Market value 174Market segmentation 175Market share 176Five forces analysis 177Leading companies 189Market forecasts 200Macroeconomic indicators 201PHARMACEUTICALS IN THE UNITED KINGDOM 203Market overview 203Market value 204Market segmentation 205Market share 206Five forces analysis 207Leading companies 219Market forecasts 231Macroeconomic indicators 232PHARMACEUTICALS IN THE UNITED STATES 234Market overview 234Market value 235Market segmentation 236Market share 237Five forces analysis 238Leading companies 249Market forecasts 265Macroeconomic indicators 266APPENDIX 268Data Research Methodology 268About Datamonitor 269Disclaimer 269

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($m), 2006–15 18

Table 2: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 21

Table 3: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 23

Table 4: Canada pharmaceuticals market value: $ million, 2006–10 25

Table 5: Canada pharmaceuticals market segmentation: % share, by value, 2010 26

Table 6: Canada pharmaceuticals market share: % share, by value, 2010 27

Table 7: AstraZeneca PLC: key facts 39

Table 8: AstraZeneca PLC: key financials ($) 41

Table 9: AstraZeneca PLC: key financial ratios 41

Table 10: Johnson & Johnson: key facts 43

Table 11: Johnson & Johnson: key financials ($) 44

Table 12: Johnson & Johnson: key financial ratios 45

Table 13: Pfizer Inc.: key facts 47

Table 14: Pfizer Inc.: key financials ($) 48

Table 15: Pfizer Inc.: key financial ratios 48

Table 16: Canada pharmaceuticals market value forecast: $ million, 2010–15 50

Table 17: Canada size of population (million), 2006–10 51

Table 18: Canada gdp (constant 2000 prices, $ billion), 2006–10 51

Table 19: Canada gdp (current prices, $ billion), 2006–10 51

Table 20: Canada inflation, 2006–10 52

Table 21: Canada consumer price index (absolute), 2006–10 52

Table 22: Canada exchange rate, 2006–10 52

Table 23: France pharmaceuticals market value: $ million, 2006–10 54

Table 24: France pharmaceuticals market segmentation: % share, by value, 2010 55

Table 25: France pharmaceuticals market share: % share, by value, 2010 56

Table 26: AstraZeneca PLC: key facts 68

Table 27: AstraZeneca PLC: key financials ($) 70

Table 28: AstraZeneca PLC: key financial ratios 70

Table 29: GlaxoSmithKline Plc: key facts 72

Table 30: GlaxoSmithKline Plc: key financials ($) 74

Table 31: GlaxoSmithKline Plc: key financials (£) 75

Table 32: GlaxoSmithKline Plc: key financial ratios 75

Table 33: Pfizer Inc.: key facts 77

Table 34: Pfizer Inc.: key financials ($) 78

Table 35: Pfizer Inc.: key financial ratios 78

Table 36: France pharmaceuticals market value forecast: $ million, 2010–15 80

Table 37: France size of population (million), 2006–10 81

Table 38: France gdp (constant 2000 prices, $ billion), 2006–10 81

Table 39: France gdp (current prices, $ billion), 2006–10 81

Table 40: France inflation, 2006–10 82

Table 41: France consumer price index (absolute), 2006–10 82

Table 42: France exchange rate, 2006–10 82

Table 43: Germany pharmaceuticals market value: $ million, 2006–10 84

Table 44: Germany pharmaceuticals market segmentation: % share, by value, 2010 85

Table 45: Germany pharmaceuticals market share: % share, by value, 2010 86

Table 46: GlaxoSmithKline Plc: key facts 98

Table 47: GlaxoSmithKline Plc: key financials ($) 100

Table 48: GlaxoSmithKline Plc: key financials (£) 101

Table 49: GlaxoSmithKline Plc: key financial ratios 101

Table 50: Novartis AG: key facts 103

Table 51: Novartis AG: key financials ($) 104

Table 52: Novartis AG: key financial ratios 105

Table 53: Pfizer Inc.: key facts 107

Table 54: Pfizer Inc.: key financials ($) 108

Table 55: Pfizer Inc.: key financial ratios 108

Table 56: Germany pharmaceuticals market value forecast: $ million, 2010–15 110

Table 57: Germany size of population (million), 2006–10 111

Table 58: Germany gdp (constant 2000 prices, $ billion), 2006–10 111

Table 59: Germany gdp (current prices, $ billion), 2006–10 111

Table 60: Germany inflation, 2006–10 112

Table 61: Germany consumer price index (absolute), 2006–10 112

Table 62: Germany exchange rate, 2006–10 112

Table 63: Italy pharmaceuticals market value: $ million, 2006–10 114

Table 64: Italy pharmaceuticals market segmentation: % share, by value, 2010 115

Table 65: Italy pharmaceuticals market share: % share, by value, 2010 116

Table 66: Chiesi Farmaceutici SpA: key facts 128

Table 67: GlaxoSmithKline Plc: key facts 131

Table 68: GlaxoSmithKline Plc: key financials ($) 133

Table 69: GlaxoSmithKline Plc: key financials (£) 134

Table 70: GlaxoSmithKline Plc: key financial ratios 134

Table 71: Menarini Group, The: key facts 136

Table 72: Pfizer Inc.: key facts 138

Table 73: Pfizer Inc.: key financials ($) 139

Table 74: Pfizer Inc.: key financial ratios 139

Table 75: Italy pharmaceuticals market value forecast: $ million, 2010–15 141

Table 76: Italy size of population (million), 2006–10 142

Table 77: Italy gdp (constant 2000 prices, $ billion), 2006–10 142

Table 78: Italy gdp (current prices, $ billion), 2006–10 142

Table 79: Italy inflation, 2006–10 143

Table 80: Italy consumer price index (absolute), 2006–10 143

Table 81: Italy exchange rate, 2006–10 143

Table 82: Japan pharmaceuticals market value: $ million, 2006–10 145

Table 83: Japan pharmaceuticals market segmentation: % share, by value, 2010 146

Table 84: Japan pharmaceuticals market share: % share, by value, 2010 147

Table 85: Astellas: key facts 159

Table 86: Astellas: key financials ($) 160

Table 87: Astellas: key financials (¥) 161

Table 88: Astellas: key financial ratios 161

Table 89: Daiichi Sankyo Co., Ltd.: key facts 163

Table 90: Daiichi Sankyo Co., Ltd.: key financials ($) 164

Table 91: Daiichi Sankyo Co., Ltd.: key financials (¥) 164

Table 92: Daiichi Sankyo Co., Ltd.: key financial ratios 165

Table 93: Pfizer Inc.: key facts 167

Table 94: Pfizer Inc.: key financials ($) 168

Table 95: Pfizer Inc.: key financial ratios 168

Table 96: Japan pharmaceuticals market value forecast: $ million, 2010–15 170

Table 97: Japan size of population (million), 2006–10 171

Table 98: Japan gdp (constant 2000 prices, $ billion), 2006–10 171

Table 99: Japan gdp (current prices, $ billion), 2006–10 171

Table 100: Japan inflation, 2006–10 172

Table 101: Japan consumer price index (absolute), 2006–10 172

Table 102: Japan exchange rate, 2006–10 172

Table 103: Russia pharmaceuticals market value: $ million, 2006–10 174

Table 104: Russia pharmaceuticals market segmentation: % share, by value, 2010 175

Table 105: Russia pharmaceuticals market share: % share, by value, 2010 176

Table 106: Novartis AG: key facts 189

Table 107: Novartis AG: key financials ($) 190

Table 108: Novartis AG: key financial ratios 191

Table 109: Pharmstandard OJSC: key facts 193

Table 110: Pharmstandard OJSC: key financials ($) 194

Table 111: Pharmstandard OJSC: key financials (RUB) 194

Table 112: Pharmstandard OJSC: key financial ratios 194

Table 113: Sanofi-Aventis SA: key facts 196

Table 114: Sanofi-Aventis SA: key financials ($) 197

Table 115: Sanofi-Aventis SA: key financials (€) 197

Table 116: Sanofi-Aventis SA: key financial ratios 198

Table 117: Russia pharmaceuticals market value forecast: $ million, 2010–15 200

Table 118: Russia size of population (million), 2006–10 201

Table 119: Russia gdp (constant 2000 prices, $ billion), 2006–10 201

Table 120: Russia gdp (current prices, $ billion), 2006–10 201

Table 121: Russia inflation, 2006–10 202

Table 122: Russia consumer price index (absolute), 2006–10 202

Table 123: Russia exchange rate, 2006–10 202

Table 124: United Kingdom pharmaceuticals market value: $ million, 2006–10 204

Table 125: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205

Table 126: United Kingdom pharmaceuticals market share: % share, by value, 2010 206

Table 127: AstraZeneca PLC: key facts 219

Table 128: AstraZeneca PLC: key financials ($) 221

Table 129: AstraZeneca PLC: key financial ratios 221

Table 130: GlaxoSmithKline Plc: key facts 223

Table 131: GlaxoSmithKline Plc: key financials ($) 225

Table 132: GlaxoSmithKline Plc: key financials (£) 226

Table 133: GlaxoSmithKline Plc: key financial ratios 226

Table 134: Pfizer Inc.: key facts 228

Table 135: Pfizer Inc.: key financials ($) 229

Table 136: Pfizer Inc.: key financial ratios 229

Table 137: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231

Table 138: United Kingdom size of population (million), 2006–10 232

Table 139: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 232

Table 140: United Kingdom gdp (current prices, $ billion), 2006–10 232

Table 141: United Kingdom inflation, 2006–10 233

Table 142: United Kingdom consumer price index (absolute), 2006–10 233

Table 143: United Kingdom exchange rate, 2006–10 233

Table 144: United States pharmaceuticals market value: $ million, 2006–10 235

Table 145: United States pharmaceuticals market segmentation: % share, by value, 2010 236

Table 146: United States pharmaceuticals market share: % share, by value, 2010 237

Table 147: GlaxoSmithKline Plc: key facts 249

Table 148: GlaxoSmithKline Plc: key financials ($) 251

Table 149: GlaxoSmithKline Plc: key financials (£) 252

Table 150: GlaxoSmithKline Plc: key financial ratios 252

Table 151: Johnson & Johnson: key facts 254

Table 152: Johnson & Johnson: key financials ($) 255

Table 153: Johnson & Johnson: key financial ratios 256

Table 154: Merck & Co., Inc.: key facts 258

Table 155: Merck & Co., Inc.: key financials ($) 259

Table 156: Merck & Co., Inc.: key financial ratios 260

Table 157: Pfizer Inc.: key facts 262

Table 158: Pfizer Inc.: key financials ($) 263

Table 159: Pfizer Inc.: key financial ratios 263

Table 160: United States pharmaceuticals market value forecast: $ million, 2010–15 265

Table 161: United States size of population (million), 2006–10 266

Table 162: United States gdp (constant 2000 prices, $ billion), 2006–10 266

Table 163: United States gdp (current prices, $ billion), 2006–10 266

Table 164: United States inflation, 2006–10 267

Table 165: United States consumer price index (absolute), 2006–10 267

Table 166: United States exchange rate, 2006–10 267

LIST OF FIGURESFigure 1: G8 pharmaceuticals industry, revenue($m), 2006–15 17Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2010 19Figure 3: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 20Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 22Figure 5: Canada pharmaceuticals market value: $ million, 2006–10 25Figure 6: Canada pharmaceuticals market segmentation: % share, by value, 2010 26Figure 7: Canada pharmaceuticals market share: % share, by value, 2010 27Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2010 28Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2010 29Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2010 31Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010 33Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010 35Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010 37Figure 14: AstraZeneca PLC: revenues & profitability 42Figure 15: AstraZeneca PLC: assets & liabilities 42Figure 16: Johnson & Johnson: revenues & profitability 45Figure 17: Johnson & Johnson: assets & liabilities 46Figure 18: Pfizer Inc.: revenues & profitability 49Figure 19: Pfizer Inc.: assets & liabilities 49Figure 20: Canada pharmaceuticals market value forecast: $ million, 2010–15 50Figure 21: France pharmaceuticals market value: $ million, 2006–10 54Figure 22: France pharmaceuticals market segmentation: % share, by value, 2010 55Figure 23: France pharmaceuticals market share: % share, by value, 2010 56Figure 24: Forces driving competition in the pharmaceuticals market in France, 2010 57Figure 25: Drivers of buyer power in the pharmaceuticals market in France, 2010 58Figure 26: Drivers of supplier power in the pharmaceuticals market in France, 2010 60Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010 62Figure 28: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010 64Figure 29: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010 66Figure 30: AstraZeneca PLC: revenues & profitability 71Figure 31: AstraZeneca PLC: assets & liabilities 71Figure 32: GlaxoSmithKline Plc: revenues & profitability 76Figure 33: GlaxoSmithKline Plc: assets & liabilities 76Figure 34: Pfizer Inc.: revenues & profitability 79Figure 35: Pfizer Inc.: assets & liabilities 79Figure 36: France pharmaceuticals market value forecast: $ million, 2010–15 80Figure 37: Germany pharmaceuticals market value: $ million, 2006–10 84Figure 38: Germany pharmaceuticals market segmentation: % share, by value, 2010 85Figure 39: Germany pharmaceuticals market share: % share, by value, 2010 86Figure 40: Forces driving competition in the pharmaceuticals market in Germany, 2010 87Figure 41: Drivers of buyer power in the pharmaceuticals market in Germany, 2010 88Figure 42: Drivers of supplier power in the pharmaceuticals market in Germany, 2010 90Figure 43: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2010 92Figure 44: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2010 94Figure 45: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2010 96Figure 46: GlaxoSmithKline Plc: revenues & profitability 102Figure 47: GlaxoSmithKline Plc: assets & liabilities 102Figure 48: Novartis AG: revenues & profitability 105Figure 49: Novartis AG: assets & liabilities 106Figure 50: Pfizer Inc.: revenues & profitability 109Figure 51: Pfizer Inc.: assets & liabilities 109Figure 52: Germany pharmaceuticals market value forecast: $ million, 2010–15 110Figure 53: Italy pharmaceuticals market value: $ million, 2006–10 114Figure 54: Italy pharmaceuticals market segmentation: % share, by value, 2010 115Figure 55: Italy pharmaceuticals market share: % share, by value, 2010 116Figure 56: Forces driving competition in the pharmaceuticals market in Italy, 2010 117Figure 57: Drivers of buyer power in the pharmaceuticals market in Italy, 2010 118Figure 58: Drivers of supplier power in the pharmaceuticals market in Italy, 2010 120Figure 59: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2010 122Figure 60: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2010 124Figure 61: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2010 126Figure 62: GlaxoSmithKline Plc: revenues & profitability 135Figure 63: GlaxoSmithKline Plc: assets & liabilities 135Figure 64: Pfizer Inc.: revenues & profitability 140Figure 65: Pfizer Inc.: assets & liabilities 140Figure 66: Italy pharmaceuticals market value forecast: $ million, 2010–15 141Figure 67: Japan pharmaceuticals market value: $ million, 2006–10 145Figure 68: Japan pharmaceuticals market segmentation: % share, by value, 2010 146Figure 69: Japan pharmaceuticals market share: % share, by value, 2010 147Figure 70: Forces driving competition in the pharmaceuticals market in Japan, 2010 148Figure 71: Drivers of buyer power in the pharmaceuticals market in Japan, 2010 149Figure 72: Drivers of supplier power in the pharmaceuticals market in Japan, 2010 151Figure 73: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2010 153Figure 74: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2010 155Figure 75: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2010 157Figure 76: Astellas: revenues & profitability 162Figure 77: Astellas: assets & liabilities 162Figure 78: Daiichi Sankyo Co., Ltd.: revenues & profitability 165Figure 79: Daiichi Sankyo Co., Ltd.: assets & liabilities 166Figure 80: Pfizer Inc.: revenues & profitability 169Figure 81: Pfizer Inc.: assets & liabilities 169Figure 82: Japan pharmaceuticals market value forecast: $ million, 2010–15 170Figure 83: Russia pharmaceuticals market value: $ million, 2006–10 174Figure 84: Russia pharmaceuticals market segmentation: % share, by value, 2010 175Figure 85: Russia pharmaceuticals market share: % share, by value, 2010 176Figure 86: Forces driving competition in the pharmaceuticals market in Russia, 2010 177Figure 87: Drivers of buyer power in the pharmaceuticals market in Russia, 2010 179Figure 88: Drivers of supplier power in the pharmaceuticals market in Russia, 2010 181Figure 89: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2010 183Figure 90: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2010 185Figure 91: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2010 187Figure 92: Novartis AG: revenues & profitability 191Figure 93: Novartis AG: assets & liabilities 192Figure 94: Pharmstandard OJSC: revenues & profitability 195Figure 95: Sanofi-Aventis SA: revenues & profitability 198Figure 96: Sanofi-Aventis SA: assets & liabilities 199Figure 97: Russia pharmaceuticals market value forecast: $ million, 2010–15 200Figure 98: United Kingdom pharmaceuticals market value: $ million, 2006–10 204Figure 99: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205Figure 100: United Kingdom pharmaceuticals market share: % share, by value, 2010 206Figure 101: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2010 207Figure 102: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2010 209Figure 103: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2010 211Figure 104: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2010 213Figure 105: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2010 215Figure 106: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2010 217Figure 107: AstraZeneca PLC: revenues & profitability 222Figure 108: AstraZeneca PLC: assets & liabilities 222Figure 109: GlaxoSmithKline Plc: revenues & profitability 227Figure 110: GlaxoSmithKline Plc: assets & liabilities 227Figure 111: Pfizer Inc.: revenues & profitability 230Figure 112: Pfizer Inc.: assets & liabilities 230Figure 113: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231Figure 114: United States pharmaceuticals market value: $ million, 2006–10 235Figure 115: United States pharmaceuticals market segmentation: % share, by value, 2010 236Figure 116: United States pharmaceuticals market share: % share, by value, 2010 237Figure 117: Forces driving competition in the pharmaceuticals market in the United States, 2010 238Figure 118: Drivers of buyer power in the pharmaceuticals market in the United States, 2010 239Figure 119: Drivers of supplier power in the pharmaceuticals market in the United States, 2010 241Figure 120: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2010 243Figure 121: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2010 245Figure 122: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2010 247Figure 123: GlaxoSmithKline Plc: revenues & profitability 253Figure 124: GlaxoSmithKline Plc: assets & liabilities 253Figure 125: Johnson & Johnson: revenues & profitability 256Figure 126: Johnson & Johnson: assets & liabilities 257Figure 127: Merck & Co., Inc.: revenues & profitability 260Figure 128: Merck & Co., Inc.: assets & liabilities 261Figure 129: Pfizer Inc.: revenues & profitability 264Figure 130: Pfizer Inc.: assets & liabilities 264Figure 131: United States pharmaceuticals market value forecast: $ million, 2010–15 265

To order this report:Pharmaceutical Industry: Pharmaceuticals - Global Group of Eight (G8) Industry Guide

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):